This will be a Phase 1, open label, imaging study of radiochemical and radiation safety in healthy volunteers. Using positron emission tomography (PET) and in-line computed tomography (CT), the whole body (WB) biokinetics of Carbon-11 butanol will be quantified with serial scans acquired every 3 minutes for two hours. Vital signs (VS), electrocardiograms (ECGs) and clinical laboratory tests of intrernal organ function will be acquired before and at several timepoints after administration of the radiopharmaceutical. Radiation exposures will be estimated with the MIRD Formalism.
Vital signs (VSs) will be measured, electrocardiograms (ECGs) will be acquired, and blood will be sent to the clinical laboratory for safety assessments before a single dose, intravenous (IV) administration of 555 MBq of Carbon-11 butanol. VSs will be re-measured, ECGs will be acquired again, and more blood will be sent to the clinical laboratory for repeat safety assessments after 2 hours of whole body (WB) scanning. WB scanning will consist of imaging acquisition sweeps of 200 cm from head-to-toe over 180 secs (3 min). Up to 40 sweeps per imaging session will be performed. The subjects will then be given a rest period ("coffee break") for about two hours, after which the entire sequence of events will be repeated. The primary outcome measure will be related to radiation safety derived from the areas under the time-activity curves (AUCs) for internal organs. Co-primary clinical safety measures will include changes in VSs, ECG parameters such as the PR and corrected QT intervals, and clinical laboratory tests, such as proteins that reflect renal and hepatic function. Secondary endpoints will include the time-activity curves (TACs) and total volumes of distribution (VT) in several brain regions. The results should allow calculation of the repeatability coefficients (RCs) under zero-biological-change conditions. RC values will be essential for understanding whether future measurements of effect sizes in response to therapeutic maneuvers or the differences between groups are meaningful.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
5
Two sequential administrations of a PET tracer
Weill Cornell Medicine
New York, New York, United States
Effective Dose (ED)
Fundamental radiation dose quantity in the International Commission on Radiological Protection (ICRP) system of radiological protection. Calculated with OLINDA-EXM software (OLINDA/EXM stands for Organ Level INternal Dose Assessment/EXponential Modeling).
Time frame: Day 1, from the measurements of exposures during the first 2 hours post administration.
Change in Radiochemical Safety Assessments
Change in pulse
Time frame: Pulse at two hours post administration compared to pulse shortly before administration.
Change in Radiochemical Safety Assessments
Change in blood pressure
Time frame: Blood pressure at two hours post administration compared to blood pressure shortly before administration.
Change in Radiochemical Safety Assessments
Change in heart rhythm on electrocardiogram (ECG)
Time frame: At two hours post administration compared to same parameters shortly before administration.
Change in number of Subjects with prolonged PR interval greater than 20 mSec
Change in PR interval on electrocardiogram (ECG)
Time frame: At two hours post administration compared to same parameters shortly before administration.
Change in number of subjects with QTc >440 mSec
Change in corrected QT interval on electrocardiogram (ECG).
Time frame: At two hours post administration compared to same parameters shortly before administration.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.